About atrium therapeutics inc - RNA
Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.
RNA At a Glance
Atrium Therapeutics, Inc.
10578 Science Center Drive
San Diego, California 92121
| Phone | 1-619-876-0700 | Revenue | 18.62M | |
| Industry | Biotechnology | Net Income | -49,501,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 70.854% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
RNA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
RNA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | 186.18 |
| Total Asset Turnover | 2.106 |
RNA Liquidity
| Current Ratio | 0.039 |
| Quick Ratio | 0.039 |
| Cash Ratio | N/A |
RNA Profitability
| Gross Margin | 98.265 |
| Operating Margin | -266.575 |
| Pretax Margin | -266.64 |
| Net Margin | -265.877 |
| Return on Assets | -559.966 |
| Return on Equity | N/A |
| Return on Total Capital | 83.842 |
| Return on Invested Capital | N/A |
RNA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -6.219 |
| Total Debt to Total Assets | 41.037 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |